Targacept is “one of the best specs I have ever seen,” Cramer said Friday. The company hopes to find partnership for a key anti-depressant drug by the end of the year, and the Mad Money host recommended that investors get in ahead of that, if they’re looking for a little speculation.
The treatment in question is TC-5214, for which the company released positive Phase II data back on Oct. 15. Targacept rallied $4 on the news, but has since dropped back down to pre-report levels. That offers a great entry point for anyone who wants to build a position in the stock.
So should you buy it? Watch the video for Cramer’s full report. He reviews TC-5214 in full, highlights Targacept’s other drugs and analyzes the company’s balance sheet and more.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org